Cellosaurus logo
expasy logo

Cellosaurus HCC827 GR2 (CVCL_V621)

[Text version]
Cell line name HCC827 GR2
Accession CVCL_V621
Resource Identification Initiative To cite this cell line use: HCC827 GR2 (RRID:CVCL_V621)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
Derived from site: In situ; Lung; UBERON=UBERON_0002048.
Sequence variations
  • Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line).
  • Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
Disease Lung adenocarcinoma (NCIt: C3512)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2063 (HCC827)
Sex of cell Female
Age at sampling 39Y
Category Cancer cell line

PubMed=17463250; DOI=10.1126/science.1141478
Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N.I., Gale C.-M., Zhao X.-J., Christensen J.G., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science 316:1039-1043(2007)

Cell line databases/resources cancercelllines; CVCL_V621
Encyclopedic resources Wikidata; Q54881789
Gene expression databases GEO; GSM466321
Polymorphism and mutation databases Progenetix; CVCL_V621
Entry history
Entry creation16-Apr-2014
Last entry update05-Oct-2023
Version number15